STAMFORD, Conn. — Purdue Pharma announced that it has reached a new settlement with states and droves of local governments amid a court battle over the country’s role in the opioid crisis. Today’s news comes after a previous settlement was appealed by eight states and Washington, D.C., last year. “We’re pleased with the settlement achieved
STAMFORD, Conn. — Purdue Pharma has filed a Chapter 11 plan of reorganization (the Plan) and a related disclosure statement in the United States Bankruptcy Court for the Southern District of New York. True to the vision articulated at the outset of the Chapter 11 proceedings, the Plan charts a path for more than $10
STAMFORD, Conn. – Purdue Pharma announced Wednesday that it has entered into an $8.3 billion agreement with the United States Department of Justice (DOJ) to resolve multi-year civil and criminal investigations into the company’s past marketing practices related to its opioid medicines. With the agreement, Purdue accepts responsibility for specified misconduct that took place before
STAMFORD, Conn.— Purdue Pharma announced on Sunday that it has filed for bankruptcy protection under the new agreement the company reached in principle on a framework for settling the U.S. opioid litigation facing the company with 24 state attorneys general, analogous officials from 5 U.S. territories, the Plaintiffs’ executive committee in the multidistrict litigation (MDL),
STAMFORD, Conn. — Craig Landau has been promoted to president and chief executive officer of Purdue Pharma L.P. With the move, Landau — who retains his duties as president and CEO of Purdue’s Canadian operations — takes the chief executive reins from Mark Timney, who the company said is leaving to pursue other career opportunities.
WASHINGTON — Purdue Pharma L.P. has become a member of health policy research group The National Pharmaceutical Council (NPC). NPC said Dr. Tracy Mayne, head of medical affairs strategic research at Purdue Pharma, will serve as the pharmaceutical company’s representative on the NPC board of directors. “NPC’s research and activities are helping to drive the discussion
BALTIMORE — Lupin Pharmaceuticals Inc., the U.S. arm of India-based Lupin Ltd., has launched the first product from its Gavis pipeline, zolpidem sublingual tablets 1.75 mg and 3.5 mg, an insomnia drug. Lupin said its product is a generic version of Intermezzo sublingual tablets (1.75 mg and 3.5 mg) from Purdue Pharma. The Lupin generic received